Brokerages Set Altimmune, Inc. (NASDAQ:ALT) Target Price at $20.00

Shares of Altimmune, Inc. (NASDAQ:ALT) have received a consensus recommendation of “Moderate Buy” from the nine brokerages that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $19.71.

ALT has been the topic of several analyst reports. Stifel Nicolaus began coverage on shares of Altimmune in a research report on Wednesday. They set a “buy” rating and a $18.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research note on Thursday, November 14th. Finally, UBS Group initiated coverage on Altimmune in a research report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target on the stock.

Altimmune Stock Up 1.9 %

Shares of Altimmune stock opened at $7.45 on Tuesday. Altimmune has a 52 week low of $5.28 and a 52 week high of $14.84. The firm has a market capitalization of $529.88 million, a P/E ratio of -4.81 and a beta of 0.22. The company has a 50 day moving average price of $8.10 and a 200 day moving average price of $7.20.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The company had revenue of $0.01 million during the quarter. During the same period in the prior year, the firm posted ($0.39) EPS. As a group, research analysts anticipate that Altimmune will post -1.36 earnings per share for the current fiscal year.

Institutional Trading of Altimmune

A number of large investors have recently bought and sold shares of ALT. Dimensional Fund Advisors LP boosted its holdings in shares of Altimmune by 142.9% in the second quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock valued at $3,791,000 after acquiring an additional 335,444 shares in the last quarter. Bellevue Group AG boosted its position in shares of Altimmune by 43.9% in the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock worth $5,303,000 after buying an additional 263,660 shares in the last quarter. Virtu Financial LLC purchased a new position in Altimmune during the 3rd quarter valued at about $674,000. Los Angeles Capital Management LLC acquired a new stake in shares of Altimmune in the second quarter valued at approximately $689,000. Finally, Exchange Traded Concepts LLC lifted its stake in Altimmune by 74.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 216,761 shares of the company’s stock valued at $1,331,000 after buying an additional 92,498 shares in the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.